Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
558 stopped studies mapped to Acute Myeloid Leukemia and descendants · 90% state a reason
Over the 558 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or… | Phase 3 | terminated | Nov 21, 2014 | University of Ulm | The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an… | Drug supply |
| NCT03473457 | CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia(AML) | N/A | terminated | Mar 22, 2018 | Zhujiang Hospital | The therapeutic effect was not as expected | Other (stated, no rule matched) |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | N/A | terminated | Apr 7, 2014 | Rutgers, The State University of New Jersey | No patients were eligible to receive the experimental component of the protocol therapy. | Other (stated, no rule matched) |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy…(HINKL) | Phase 2 | terminated | Sep 1, 2014 | Technische Universität Dresden | low recruitment rate | Enrollment / accrual |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | terminated | Apr 30, 2010 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04296214 | Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic… | — | withdrawn | Mar 5, 2020 | Grupo Cooperativo de Hemopatías Malignas | Poor recruitment | Enrollment / accrual |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in… | Phase 1 / Phase 2 | terminated | May 12, 2015 | University of Illinois at Chicago | not stated | Not stated |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute… | Phase 1 / Phase 2 | terminated | Dec 7, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03806192 | Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid… | N/A | terminated | Jan 16, 2019 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04395092 | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and… | Phase 2 | withdrawn | May 20, 2020 | Kiadis Pharma | The sponsor decided to withdraw this study | Sponsor / business decision |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD… | Phase 3 | withdrawn | Feb 28, 2017 | Loyola University | No participants were enrolled | Enrollment / accrual |
| NCT01599429 | Study of the Predictive Marker FLT in Patients Suffering From AML(TEP-FLT-LMA) | — | withdrawn | May 16, 2012 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | No participants enrolled | Enrollment / accrual |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | N/A | terminated | Sep 14, 2012 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT03125876 | A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Apr 24, 2017 | Sunshine Lake Pharma Co., Ltd. | Company strategy adjustment | Sponsor / business decision |
| NCT03360006 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With… | Phase 1 | terminated | Dec 2, 2017 | AbbVie | Strategic Reasons | Sponsor / business decision |
| NCT02648932 | The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With… | Phase 2 | terminated | Jan 7, 2016 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | Phase 1 / Phase 2 | terminated | Apr 13, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03881735 | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With… | Phase 2 | withdrawn | Mar 19, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT03515707 | Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal… | Phase 2 | withdrawn | May 3, 2018 | Fred Hutchinson Cancer Center | PI recommended closure | Other (stated, no rule matched) |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | Phase 2 | terminated | Feb 14, 2008 | Abramson Cancer Center at Penn Medicine | Study terminated. Eisai's Targretin acquired by another pharmaceutical company. | Sponsor / business decision |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell… | Phase 2 | terminated | Oct 17, 2018 | Milton S. Hershey Medical Center | Funding pulled | Funding |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or… | Phase 1 / Phase 2 | withdrawn | Jul 30, 2020 | M.D. Anderson Cancer Center | The original sponsor was acquired by a new company and has elected to end funding for all… | Investigator |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | Phase 1 / Phase 2 | terminated | Aug 2, 2012 | PrECOG, LLC. | Study stopped per Novartis request due to futility from another study. | Efficacy / futility |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | M.D. Anderson Cancer Center | PDOL request | Other (stated, no rule matched) |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation… | Phase 1 | withdrawn | Oct 16, 2019 | Sherif Farag | Funder withdrew funding after not accruing any subjects after 1 year. | Enrollment / accrual |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects… | Phase 2 | withdrawn | Feb 23, 2017 | Immune System Key Ltd | No recruitment since initiation | Enrollment / accrual |
| NCT04106076 | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | Phase 1 | withdrawn | Sep 26, 2019 | Cellectis S.A. | The trial was discontinued due to sponsor's decision and not a consequence of any safety concern | Safety / toxicity |
| NCT03152526 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK)… | N/A | terminated | May 15, 2017 | Miltenyi Biotec B.V. & Co. KG | Slow enrollment | Enrollment / accrual |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic… | Phase 1 / Phase 2 | withdrawn | Jul 10, 2019 | Vanderbilt-Ingram Cancer Center | Loss of funding | Funding |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | Phase 2 | terminated | Oct 24, 2018 | NYU Langone Health | Safety concerns | Safety / toxicity |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2016 | Bio-Path Holdings, Inc. | No enrollment | Enrollment / accrual |
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or… | Phase 2 | terminated | Mar 6, 2017 | St. Jude Children's Research Hospital | Due to slow enrollment | Enrollment / accrual |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone… | Phase 1 / Phase 2 | terminated | Jan 16, 2014 | Albert Einstein College of Medicine | Low accrual | Enrollment / accrual |
| NCT01636609 | Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute… | Phase 1 | terminated | Jul 10, 2012 | M.D. Anderson Cancer Center | In 2013 the FDA put a temporary hold on the trial and the Phase II portion of this study was… | Other (stated, no rule matched) |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory…(CyFi2) | Phase 2 | withdrawn | Sep 24, 2019 | AVEO Pharmaceuticals, Inc. | Urgent shift among clinical sites toward efforts to combat COVID-19 pandemic;impacted feasibility… | COVID-19 / pandemic |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy…(UFT RT Phase 3) | Phase 3 | terminated | Sep 21, 2005 | Institut Cancerologie de l'Ouest | Terminated after interim analysis | Efficacy / futility |
| NCT02109627 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | Phase 1 | terminated | Apr 10, 2014 | C. Babis Andreadis | Low Accrual | Enrollment / accrual |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | Phase 2 | terminated | Jan 28, 2015 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese…(Japanese AML) | Phase 1 | terminated | May 1, 2017 | Gilead Sciences | No signal of efficacy with Entospletinib | Efficacy / futility |
| NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | Phase 1 | terminated | Aug 23, 2016 | Polaris Group | Study Termination | Other (stated, no rule matched) |
| NCT02341495 | Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML…(EXJADE) | Phase 2 | terminated | Jan 19, 2015 | Elizabeth Henry | Study was terminated early due to low patient accrual. | Enrollment / accrual |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid… | Phase 1 | terminated | Oct 27, 2015 | ADC Therapeutics S.A. | Slow enrollment | Enrollment / accrual |
| NCT00939653 | T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia… | Phase 2 | terminated | Jul 15, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Due to insufficient research institution participation and patient enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 6, 2021source: clinicaltrials